TCI GENE Inc. (6879.TWO)
Taipei Exchange · TWD · Healthcare · Biotechnology
NT$34.85 (-4.39%) as of
Key statistics
- Market cap
- 922.08M
- P/E (TTM)
- 18.34
- EPS (TTM)
- 1.90
- Dividend yield
- 0.00%
- 52-week range
- 32.35 – 41.05
- Beta
- 0.28
- Revenue (TTM)
- 251.39M
- Profit margin
- 20.14%
- Volume
- 1.01k
About TCI GENE Inc.
TCI GENE Inc., together with its subsidiaries, provides genetic testing and assessment services in Taiwan and Mainland China. It operates through Inspection and Consumable Products segments. The company offers memory, anti-aging, health management, child growth and development, nutritional metabolism and absorption, OB weight management, and SC skin management genetic testing; gut microbiota testing; and LDT cardiovascular drug gene testing services. It also provides precision prediction and personalized health management plans; and adipose-derived mesenchymal stem cells, natural killer immune cells, and immune cell storage programs. In addition, the company manufactures and sells testing reagents, health food, and beauty products; and health and nutritional supplements. TCI GENE Inc. was founded in 2011 and is based in Taipei, Taiwan.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Taipei, Taiwan
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.